Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
In a key patent litigation outcome, Viatris has successfully challenged Novo Nordisk’s semaglutide patent, which covers the active ingredient in the weight management drug Wegovy. The decision clears a major hurdle for Viatris to pursue generic versions of the medication, potentially impacting the competitive landscap…
Share This Article
Ready-to-post copy includes the article link.
Viatris Prevails Over Novo Nordisk in Semaglutide Patent Dispute, Paving Way for Potential Wegovy Generic In a key patent litigation outcome, Viatris has successfully challenged Novo Nordisk’s semaglutide patent, which covers the active ingredient in the weight management drug Wegovy. The decision clears a major hurdle for... Read the full IIPLA article: https://iipla.org/news/viatris-prevails-over-novo-nordisk-in-semaglutide-patent-dispute-paving-way-for-potential-wegovy-generic